Prasugrel Hydrochloride Concept

subject area of

• A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction  Journal Articles
• A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes  Journal Articles
• An optimum prophylactic dose of prasugrel monotherapy may safely and effectively prevent the development of experimental thrombotic strokes  Journal Articles
• Antiplatelet Therapy and Cardiac Surgery: Review of Recent Evidence and Clinical Implications  Journal Articles
• Are all P2Y12 equally effective in vein graft angioplasty? A report from the UK database  Journal Articles
• Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (COAPT)  Journal Articles
• Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II  Journal Articles
• Contemporary Management of ST-Elevation Myocardial Infarction  Journal Articles
• Contemporary use of guideline‐based higher potency P2Y12 receptor inhibitor therapy in patients with moderate‐to‐high risk non‐ST‐segment elevation myocardial infarction: Results from the Canadian ACS reflective II cross‐sectional study  Journal Articles
• Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy  Journal Articles
• Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes  Journal Articles
• In ACS with planned invasive evaluation, prasugrel vs ticagrelor reduced a composite of death, MI, or stroke at 1 y  Journal Articles
• Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy  Journal Articles
• New antithrombotic agents—insights from clinical trials  Journal Articles
• Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial  Journal Articles
• PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes  Journal Articles
• Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future  Journal Articles
• Role of phenotypic and genetic testing in managing clopidogrel therapy  Journal Articles
• The Pursuit of Clinically Relevant Measures of Platelet Function After Antiplatelet Drug Therapy⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.  Journal Articles
• The Value of Large Randomized Trials of Two Active Interventions to Define the Optimal Treatment in Patients With Acute Coronary Syndrome  Journal Articles
• Will prasugrel supersede clopidogrel for acute coronary syndromes?  Journal Articles